A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
← catalyst calendarSponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
51actual
Sites
28
Countries
Australia, China, New Zealand +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-20 | actual | When the study began enrolling |
| Primary completion | 2026-06-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-08 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Relapsed Follicular Lymphoma
- Relapsed Marginal Zone Lymphoma
- Relapse Diffuse Large B Cell Lymphoma
- Relapsed Small Lymphocytic Lymphoma
- Refractory Follicular Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Small Lymphocytic Lymphoma
- Richter Transformation
- Refractory Diffuse Large B-cell Lymphoma
- Transformed Non-Hodgkin Lymphoma
Intervention
- Drug: BGB-21447
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of participants with dose limiting toxicities (DLTs)
measured Up to approximately 1 month
Number of participants with adverse events (AEs)
measured From the first dose of study drug to 30 days after the last dose or initiation of new anticancer therapy, whichever occurs first; up to approximately 12 months
Number of participants with Tumor Lysis Syndrome (TLS)
measured From the first dose of study drug to 30 days after the last dose or initiation of new anticancer therapy, whichever occurs first; up to approximately 12 months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed